<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Geriatr</journal-id><journal-id journal-id-type="iso-abbrev">BMC Geriatr</journal-id><journal-title-group><journal-title>BMC Geriatrics</journal-title></journal-title-group><issn pub-type="epub">1471-2318</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22436129</article-id><article-id pub-id-type="pmc">3368715</article-id><article-id pub-id-type="publisher-id">1471-2318-12-11</article-id><article-id pub-id-type="doi">10.1186/1471-2318-12-11</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The efficacy and safety of febuxostat for urate lowering in gout patients &#x02265;65 years of age</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Jackson</surname><given-names>Robert L</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Robert.Jackson@takeda.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Hunt</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Barbara.hunt@takeda.com</email></contrib><contrib contrib-type="author" id="A3"><name><surname>MacDonald</surname><given-names>Patricia A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Patricia.macdonald@takeda.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Takeda Global Research &#x00026; Development Centers, Inc, One Takeda Parkway, Deerfield, Illinois 60015, USA</aff><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>21</day><month>3</month><year>2012</year></pub-date><volume>12</volume><fpage>11</fpage><lpage>11</lpage><history><date date-type="received"><day>3</day><month>10</month><year>2011</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2012 Jackson et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Jackson et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2318/12/11"/><abstract><sec><title>Background</title><p>The incidence of gout rises with increasing age. Management of elderly (&#x02265;65 years) gout patients can be challenging due to high rates of comorbidities, such as renal impairment and cardiovascular disease, and concomitant medication use. However, there is little data specifically addressing the efficacy and safety of available urate-lowering therapies (ULT) in the elderly. The objective of this post hoc analysis was to examine the efficacy and safety of ULT with febuxostat or allopurinol in a subset of elderly subjects enrolled in the CONFIRMS trial.</p></sec><sec><title>Methods</title><p>Hyperuricemic (serum urate [sUA] levels &#x02265; 8.0 mg/dL) gout subjects were enrolled in the 6-month, double-blind, randomized, comparative CONFIRMS trial and randomized, 1:1:1, to receive febuxostat, 40 mg or 80 mg, or allopurinol (200 mg or 300 mg based on renal function) once daily. Flare prophylaxis was provided throughout the study duration.</p><p>Study endpoints were the percent of elderly subjects with sUA &#x0003c;6.0 mg/dL at the final visit, overall and by renal function status, percent change in sUA from baseline to final visit, flare rates, and rates of adverse events (AEs).</p></sec><sec><title>Results</title><p>Of 2,269 subjects enrolled, 374 were elderly. Febuxostat 80 mg was significantly more efficacious (82.0%) than febuxostat 40 mg (61.7%; <italic>p </italic>&#x0003c; 0.001) or allopurinol (47.3%; <italic>p </italic>&#x0003c; 0.001) for achieving the primary efficacy endpoint. Febuxostat 40 mg was also superior to allopurinol in this population (<italic>p </italic>= 0.029). In subjects with mild-to-moderate renal impairment, significantly greater ULT efficacy was observed with febuxostat 40 mg (61.6%; <italic>p </italic>= 0.028) and febuxostat 80 mg (82.5%; <italic>p </italic>&#x0003c; 0.001) compared to allopurinol 200/300 mg (46.9%). Compared to allopurinol 200/300 mg, the mean percent change in sUA from baseline was significantly greater for both febuxostat 80 mg (<italic>p </italic>&#x0003c; 0.001) and febuxostat 40 mg (<italic>p </italic>= 0.011) groups. Flare rates declined steadily in all treatment groups. Rates of AEs were low and comparable across treatments.</p></sec><sec><title>Conclusions</title><p>These data suggest that either dose of febuxostat is superior to commonly prescribed fixed doses of allopurinol (200/300 mg) in subjects &#x02265;65 years of age with high rates of renal dysfunction. In addition, in this high-risk population, ULT with either drug was well tolerated.</p></sec><sec><title>Trial registration</title><p>clinicaltrials.gov <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT#00430248">NCT#00430248</ext-link></p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The average age of patients seeking care for gout in the United States is approximately 66 years [<xref ref-type="bibr" rid="B1">1</xref>]. Managing gout in the elderly (&#x02265;65 years of age) is clinically challenging as people in this demographic segment have lower creatinine clearance, a greater frequency of comorbidities, and are often taking multiple medications [<xref ref-type="bibr" rid="B2">2</xref>]. There is a dearth of evidence-based information on effective management of urate-lowering therapies (ULT) in elderly patients. Available ULT options in the United States include xanthine oxidase (XO) inhibitors, allopurinol, and febuxostat, as well as the uricosuric agent probenecid. Probenecid is not effective in gout patients with renal impairment [<xref ref-type="bibr" rid="B3">3</xref>]--30% to 60% of gout patients have some degree of renal deficiency [<xref ref-type="bibr" rid="B4">4</xref>]. Allopurinol, which has been the mainstay of chronic uric acid management, is traditionally dosed according to degree of renal impairment [<xref ref-type="bibr" rid="B5">5</xref>]. Such dose decrements often lead to reduced efficacy [<xref ref-type="bibr" rid="B6">6</xref>]. Febuxostat is a selective, novel, non-purine analog XO inhibitor [<xref ref-type="bibr" rid="B7">7</xref>] for the treatment of chronic hyperuricemia in patients with gout [<xref ref-type="bibr" rid="B8">8</xref>]. Primarily metabolized in the liver [<xref ref-type="bibr" rid="B9">9</xref>], its pharmacokinetic and pharmacodynamic profiles are not affected by age or by mild-to-moderate hepatic or renal impairment [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. In this post-hoc analysis, we report the efficacy and safety of ULT with febuxostat or allopurinol in an elderly gout population.</p></sec><sec sec-type="methods"><title>Methods</title><p>The CONFIRMS trial (NCT#00430248) was a 6-month, Phase 3, double-blind, randomized, controlled trial (RCT) further examining the comparative urate-lowering efficacy and safety of febuxostat and allopurinol [<xref ref-type="bibr" rid="B13">13</xref>]. Subjects were enrolled at 324 sites in the United States. Institutional Review Board approval was obtained, and all subjects provided written informed consent that conformed to the Declaration of Helsinki and the Health Insurance Portability and Accountability Act prior to any study-related procedure. A total of 2,269 subjects who met the American College of Rheumatology criteria for the diagnosis of gout [<xref ref-type="bibr" rid="B14">14</xref>] and had hyperuricemia (serum urate [sUA] &#x02265;8.0 mg/dL [~475 &#x003bc;mol/L; to convert an sUA value from mg/dL to &#x003bc;mol/L, multiply by 59.48]) were enrolled. Study design and subject inclusion and exclusion criteria have been previously described [<xref ref-type="bibr" rid="B13">13</xref>]. Exclusion criteria included, but were not limited to, secondary hyperuricemia, xanthinuria, severe renal impairment (estimated creatinine clearance [eCLcr] &#x0003c;30 mL/min, calculated by Cockcroft-Gault formula corrected for ideal body weight[<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]), a history of cancer within 5 years of screening, or any significant medical condition and/or conditions that would interfere with the treatment, safety, or compliance with the protocol. Subjects were randomized 1:1:1 to receive a daily dose of either febuxostat 40 mg, febuxostat 80 mg (Uloric<sup>&#x000ae;</sup>; Takeda Global Research &#x00026; Development Center, Inc, Deerfield, IL), or allopurinol (Apotex, Inc, Weston, FL). Subjects randomized to allopurinol received 300 mg daily if baseline renal function was normal (eCLcr &#x02265;90 mL/min) or mildly impaired (eCLcr 60 to &#x0003c;90 mL/min); subjects with moderate renal impairment (eCLcr 30 to &#x0003c;60 mL/min) received 200 mg daily.</p><p>Throughout the 6-month treatment period, subjects received prophylaxis for gout flares, with either colchicine (Westward Pharmaceutical Corporation, Eatontown, NJ), 0.6 mg daily, or naproxen (Westward Pharmaceutical Corporation, Eatontown, NJ), 250 mg twice daily. Subjects with eCLcr &#x0003c;50 mL/min were not given naproxen. All subjects receiving naproxen prophylaxis also received lansoprazole 15 mg daily (Takeda Global Research &#x00026; Development Center, Inc, Deerfield, IL). If subjects could not tolerate either colchicine or naproxen, they could be prescribed other medications for flare prophylaxis.</p><p>The primary efficacy endpoint of CONFIRMS was the proportion of subjects who achieved a target level of sUA &#x0003c;6.0 mg/dL (~360 &#x003bc;mol/L) at final visit. Additional efficacy endpoints included the proportion of subjects with mild or moderate renal impairment with a final sUA &#x0003c;6.0 mg/dL and percent change in sUA from baseline to final visit in each treatment group. Self-reported acute gout flares requiring treatment and adverse events (AEs) were collected throughout the study; flares were not considered AEs. Flares were defined as acute episodes of joint swelling, pain, exquisite tenderness and warmth, and redness at the joint, along with the overlying skin being tense, warm, shiny, and purplish or red in color. Clinical laboratory tests were performed every 2 months. All AEs were coded using Medical Dictionary for Regulatory Activities terminology. Flare rates were summarized by 2-month periods. Our current analyses assessed the primary and secondary efficacy endpoints and safety among subjects &#x02265;65 years of age (N = 374).</p><p>Statistical analyses of the efficacy endpoints and AE rates have been previously described in detail [<xref ref-type="bibr" rid="B13">13</xref>]. In the primary CONFIRMS analysis of the total cohort (N = 2,269), non-inferiority of febuxostat 40 mg compared to allopurinol was demonstrated. Binomial 95% confidence intervals (CIs) were calculated for the difference between the 2 groups in achieving the primary efficacy endpoint. Non-inferiority was declared if the lower limit of the 95% CI for difference in the proportion of subjects achieving an sUA &#x0003c;6.0 mg/dL at the final visit was greater than &#x02212;10%. The difference between the febuxostat 40 mg group (45.2%) and the allopurinol group (42.1%) was 3.1% (95% CI:-1.9%-8.1%), thus demonstrating non-inferiority [<xref ref-type="bibr" rid="B13">13</xref>]. Last observation carried forward (LOCF) was used to account for missing data in the primary analysis. For subjects who prematurely discontinued the study before the Month 6 visit, the sUA value obtained at the last completed visit was used as the final visit. For the primary endpoint, pairwise comparisons were made between treatment groups shown to be non-inferior with Fisher's exact test. Statistical significance of mean percent change from baseline between treatment groups was determined using ANOVA. All primary and secondary efficacy analyses were performed on the intent-to-treat (ITT) population, which was defined as all randomized subjects who had a baseline sUA &#x02265;8.0 mg/dL and received at least 1 dose of study drug. Safety analysis was carried out on all randomized subjects who received at least 1 dose of study drug.</p></sec><sec sec-type="results"><title>Results</title><p>Three hundred seventy-four subjects &#x02265;65 years of age who met all of the inclusion and none of the exclusion criteria were enrolled in the CONFIRMS study. Of these, 115, 128, and 131 were randomized to receive daily febuxostat 40 mg, febuxostat 80 mg, or allopurinol 200/300 mg, respectively. Among those randomized to receive allopurinol, 80/131 (61.1%) subjects had moderate renal impairment and therefore received 200 mg daily.</p><p>Figure <xref ref-type="fig" rid="F1">1</xref> illustrates the flow of subjects &#x02265;65 years of age through the study. Of the 374 subjects, 83 (22.2%) discontinued prematurely; 28 (7.5%) discontinuations occurred during the first 30 days. Premature discontinuation rates were similar across treatment groups. The primary reason for premature discontinuation was AEs (n = 53; 14.2%).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Flow of Subjects Through the Study</bold>.</p></caption><graphic xlink:href="1471-2318-12-11-1"/></fig><p>Demographics, baseline characteristics, and medical histories were similar across treatment groups (Table <xref ref-type="table" rid="T1">1</xref>). Subjects were predominantly male (85.8%), Caucasian (84.8%), and obese (51.3%; body mass index &#x02265;30 kg/m<sup>2</sup>), with a mean age of 71 years. Mean duration of gout was 14.6 years and mean baseline sUA was 9.4 mg/dL. Tophi and kidney stones were present in 19.3% and 19.8% of subjects, respectively. Mild or moderate renal impairment was determined in 139 (37.2%) and 229 (61.2%) subjects, respectively. Comorbidities were common; in addition to the predominance of renal impairment, the majority of subjects (87.2%) had some history of cardiovascular disease, inclusive of, but not limited to, hypertension (82.4%), coronary artery disease (24.3%), cardiac arrhythmia (21.1%), and myocardial infarction (10.7%). In addition, 59.6% of elderly subjects had a history of hyperlipidemia and 24.6% were diabetic.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographics, baseline characteristics, and comorbidities<sup>a</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left">Febuxostat 40 mg<break/>N = 115</th><th align="left">Febuxostat 80 mg<break/>N = 128</th><th align="left">Allopurinol 200/300 mg<break/>N = 131</th></tr></thead><tbody><tr><td align="left"><bold>Gender</bold>, n (%)</td><td/><td/><td/></tr><tr><td align="left">Male</td><td align="left">104 (90.4)</td><td align="left">109 (85.2)</td><td align="left">108 (82.4)</td></tr><tr><td align="left">Female</td><td align="left">11 (9.6)</td><td align="left">19 (14.8)</td><td align="left">23 (17.6)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left"><bold>Race</bold>, n (%)</td><td/><td/><td/></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">American Indian or Alaska Native</td><td align="left">1 (0.9)</td><td align="left">1 (0.8)</td><td align="left">0</td></tr><tr><td align="left">Asian</td><td align="left">2 (1.7)</td><td align="left">4 (3.1)</td><td align="left">5 (3.8)</td></tr><tr><td align="left">Black or African American</td><td align="left">10 (8.7)</td><td align="left">16 (12.5)</td><td align="left">8 (6.1)</td></tr><tr><td align="left">Native Hawaiian or Other Pacific Islander</td><td align="left">1 (0.9)</td><td align="left">2 (1.6)</td><td align="left">0</td></tr><tr><td align="left">White</td><td align="left">98 (85.2)</td><td align="left">103 (80.5)</td><td align="left">116 (88.5)</td></tr><tr><td align="left">Other</td><td align="left">3 (2.6)</td><td align="left">2 (1.6)</td><td align="left">2 (1.5)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left"><bold>Ethnicity</bold>, n (%)</td><td/><td/><td/></tr><tr><td align="left">Hispanic or Latino</td><td align="left">2 (1.7)</td><td align="left">3 (2.3)</td><td align="left">9 (6.9)</td></tr><tr><td align="left">Not Hispanic or Latino</td><td align="left">113 (98.3)</td><td align="left">125 (97.7)</td><td align="left">122 (93.1)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left"><bold>Age (years)</bold></td><td/><td/><td/></tr><tr><td align="left">Mean &#x000b1; SD</td><td align="left">70.8 &#x000b1; 5.19</td><td align="left">71.2 &#x000b1; 5.22</td><td align="left">70.1 &#x000b1; 4.59</td></tr><tr><td align="left">Range</td><td align="left">65-85</td><td align="left">65-85</td><td align="left">65-85</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left"><bold>Body mass index (kg/m<sup>2</sup>)</bold></td><td/><td/><td/></tr><tr><td align="left">Mean &#x000b1; SD</td><td align="left">31.0 &#x000b1; 5.47</td><td align="left">30.7 &#x000b1; 5.13</td><td align="left">31.6 &#x000b1; 5.60</td></tr><tr><td align="left">Range</td><td align="left">20-48</td><td align="left">16-49</td><td align="left">22-48</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left"><bold>Alcohol use</bold>, n (%)</td><td/><td/><td/></tr><tr><td align="left">Non-/Ex-drinker</td><td align="left">42 (36.5)</td><td align="left">49 (38.3)</td><td align="left">53 (40.5)</td></tr><tr><td align="left">Drinker (1-14 drinks/week)</td><td align="left">73 (63.5)</td><td align="left">79 (61.7)</td><td align="left">78 (59.5)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left"><bold>Serum urate (mg/dL)</bold></td><td/><td/><td/></tr><tr><td align="left">Mean &#x000b1; SD</td><td align="left">9.4 &#x000b1; 1.14</td><td align="left">9.5 &#x000b1; 1.17</td><td align="left">9.3 &#x000b1; 1.04</td></tr><tr><td align="left">Range</td><td align="left">8-14</td><td align="left">8-13</td><td align="left">8-13</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left"><bold>Years with gout</bold></td><td/><td/><td/></tr><tr><td align="left">Mean &#x000b1; SD</td><td align="left">15.0 &#x000b1; 11.3</td><td align="left">14.8 &#x000b1; 12.40</td><td align="left">14.1 &#x000b1; 12.44</td></tr><tr><td align="left">Range</td><td align="left">0-53</td><td align="left">0-50</td><td align="left">0-48</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left"><bold>Tophi present</bold>, n (%)</td><td/><td/><td/></tr><tr><td align="left">No</td><td align="left">93 (80.9)</td><td align="left">104 (81.3)</td><td align="left">105 (80.2)</td></tr><tr><td align="left">Yes</td><td align="left">22 (19.1)</td><td align="left">24 (18.8)</td><td align="left">26 (19.8)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left"><bold>Participated in a previous febuxostat study<sup>b</sup></bold>, n (%)</td><td/><td/><td/></tr><tr><td align="left">Yes</td><td align="left">18 (15.7)</td><td align="left">23 (18.0)</td><td align="left">21 (16.0)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left"><bold>Prior urate lowering therapies</bold>, n (%)</td><td/><td/><td/></tr><tr><td align="left">No</td><td align="left">31 (27.0)</td><td align="left">34 (26.6)</td><td align="left">44 (33.6)</td></tr><tr><td align="left">Yes (any)</td><td align="left">84 (73.0)</td><td align="left">94 (73.4)</td><td align="left">87 (66.4)</td></tr><tr><td align="left">Febuxostat</td><td align="left">17 (14.8)</td><td align="left">21 (16.4)</td><td align="left">18 (13.7)</td></tr><tr><td align="left">Allopurinol</td><td align="left">76 (66.1)</td><td align="left">85 (66.4)</td><td align="left">75 (57.3)</td></tr><tr><td align="left">Probenecid</td><td align="left">5 (4.3)</td><td align="left">6 (4.7)</td><td align="left">6 (4.6)</td></tr><tr><td align="left">Other</td><td align="left">4 (3.5)</td><td align="left">4 (3.1)</td><td align="left">3 (2.3)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left"><bold>Renal Function<sup>c</sup></bold>, n (%)</td><td/><td/><td/></tr><tr><td align="left">Moderately Impaired</td><td align="left">67 (58.3)</td><td align="left">82 (64.1)</td><td align="left">80 (61.1)</td></tr><tr><td align="left">Mildly Impaired</td><td align="left">45 (39.1)</td><td align="left">44 (34.4)</td><td align="left">50 (38.2)</td></tr><tr><td align="left">Normal</td><td align="left">3 (2.6)</td><td align="left">2 (1.6)</td><td align="left">1 (0.8)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left"><bold>Medical History</bold>, n (%)</td><td/><td/><td/></tr><tr><td align="left">Any cardiovascular disease<sup>d</sup></td><td align="left">102 (88.7)</td><td align="left">108 (84.4)</td><td align="left">116 (88.5)</td></tr><tr><td align="left">Hypertension</td><td align="left">98 (85.2)</td><td align="left">102 (79.7)</td><td align="left">108 (82.4)</td></tr><tr><td align="left">Coronary artery disease</td><td align="left">26 (22.6)</td><td align="left">28 (21.9)</td><td align="left">37 (28.2)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Cardiac arrhythmia</td><td align="left">16 (13.9)</td><td align="left">28 (21.9)</td><td align="left">35 (26.7)</td></tr><tr><td align="left">Diabetes</td><td align="left">23 (20.0)</td><td align="left">35 (27.3)</td><td align="left">34 (26.0)</td></tr><tr><td align="left">Hypercholesterolemia</td><td align="left">15 (13.0)</td><td align="left">10 (7.8)</td><td align="left">17 (13.0)</td></tr><tr><td align="left">Hyperlipidemia</td><td align="left">66 (57.4)</td><td align="left">73 (57.0)</td><td align="left">84 (64.1)</td></tr><tr><td align="left">Use of low-dose aspirin (&#x02264;325 mg daily)</td><td align="left">48 (41.7)</td><td align="left">52 (40.6)</td><td align="left">49 (37.4)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>There were no statistically significant differences among treatment groups with respect to the distribution of baseline characteristics.</p><p><sup>b</sup>Subjects previously enrolled in prior febuxostat clinical trials were permitted to enroll in the CONFIRMS trial.</p><p><sup>c</sup>Moderate baseline renal impairment: estimated creatinine clearance (eCLcr) 30- &#x0003c; 60 mL/min; mild baseline renal impairment: eCLcr 60- &#x0003c; 90 mL/min; normal: eCLcr &#x02265;90 mL/min. </p><p><sup>d</sup> Any cardiovascular disease includes myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft procedure, coronary artery disease, transient ischemic attack, peripheral vascular disease, cardiac arrhythmia, venous thrombotic event, valvular heart disease, congestive heart disease, and hypertension. SD = Standard deviation</p></table-wrap-foot></table-wrap><p>Concomitant medication use was high in this population and comparable across treatment groups (Table <xref ref-type="table" rid="T2">2</xref>). Sixty percent of elderly subjects were taking at least one medication that acted on the renin-angiotensin system, 50% were taking an antithrombotic agent, while 24% were taking at least 1 diuretic. Colchicine was the primary gout flare prophylaxis used by elderly subjects (83.7%), while 10.4% received naproxen. The remaining 5.9% of subjects received indomethacin, nabumetone, prednisone, or celecoxib as flare prophylaxis.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Selected concomitant medication use among elderly subjects during the CONFIRMS trial</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left">Febuxostat 40 mg<break/>N = 115</th><th align="left">Febuxostat 80 mg<break/>N = 128</th><th align="left">Allopurinol 200/300 mg<break/>N = 131</th></tr></thead><tbody><tr><td/><td/><td align="center"><bold>n (%)</bold></td><td/></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left"><bold>Subjects with one or more concomitant medication</bold></td><td/><td/><td/></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Agents acting on the renin-angiotensin system<sup>a</sup></td><td align="left">65 (57)</td><td align="left">78 (61)</td><td align="left">83 (63)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Analgesics</td><td align="left">23 (20)</td><td align="left">33 (26)</td><td align="left">27 (21)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Antiinflammatory and antirheumatic products</td><td align="left">26 (23)</td><td align="left">32 (25)</td><td align="left">26 (20)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Antithrombotic agents</td><td align="left">58 (50)</td><td align="left">65 (51)</td><td align="left">65 (50)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Beta blockers</td><td align="left">45 (39)</td><td align="left">43 (34)</td><td align="left">55 (42)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Calcium channel blockers</td><td align="left">19 (17)</td><td align="left">21 (16)</td><td align="left">30 (23)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Corticosteroids for systemic use</td><td align="left">12 (10)</td><td align="left">21 (16)</td><td align="left">15 (11)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Drugs for acid-related gastrointestinal disorders</td><td align="left">23 (20)</td><td align="left">32 (25)</td><td align="left">34 (26)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Drugs used in diabetes</td><td align="left">20 (17)</td><td align="left">25 (20)</td><td align="left">29 (22)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Diuretics</td><td align="left">26 (23)</td><td align="left">32 (25)</td><td align="left">33 (25)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Lipid modifying agents</td><td align="left">64 (56)</td><td align="left">69 (54)</td><td align="left">75 (57)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Other antihypertensives<sup>b</sup></td><td align="left">13 (11)</td><td align="left">4 (3)</td><td align="left">10 (8)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Agents acting on the renin-angiotensin system include a direct renin inhibitor, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors.</p><p><sup>b</sup>Includes vasodilators, alpha-blockers, and &#x003b1;-adrenergic receptor agonists.</p></table-wrap-foot></table-wrap><p>Achievement of the primary efficacy endpoint, sUA &#x0003c;6.0 mg/dL at final visit, occurred in 47.3%, 61.7%, and 82.0% of subjects in the allopurinol 200/300 mg, febuxostat 40 mg, and febuxostat 80 mg groups, respectively (Figure <xref ref-type="fig" rid="F2">2</xref>). Febuxostat 80 mg was significantly more efficacious than febuxostat 40 mg or allopurinol for achieving the primary efficacy endpoint (<italic>p </italic>&#x0003c; 0.001 for both comparisons). In addition, febuxostat 40 mg was superior to allopurinol in this elderly gout population (<italic>p </italic>= 0.029).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Achievement of sUA &#x0003c;6.0 mg/dL--All Subjects (Primary Endpoint) and by Renal Function</bold>. Data regarding the percentage of subjects with normal renal function with sUA &#x0003c;6.0 mg/dL is not presented due to the low number of subjects in this group (N = 6). <sup>a</sup><italic>p </italic>= 0.029 vs allopurinol; <sup>b</sup><italic>p </italic>&#x02264; 0.001 vs febuxostat 40 mg; <sup>c</sup><italic>p </italic>&#x0003c; 0.001 vs allopurinol; <sup>d</sup><italic>p </italic>= 0.004 vs allopurinol.</p></caption><graphic xlink:href="1471-2318-12-11-2"/></fig><p>In subjects with any renal impairment (mild or moderate), the urate-lowering efficacies (sUA of &#x0003c;6.0 mg/dL at final visit) of both febuxostat 40 mg (69/112; 61.6%) and febuxostat 80 mg (104/126; 82.5%) were significantly better than that of allopurinol 200/300 mg (61/130; 46.9%; <italic>p </italic>= 0.028 vs febuxostat 40 mg; <italic>p </italic>&#x0003c; 0.001 vs febuxostat 80 mg). Achievement of sUA &#x0003c;6.0 mg/dL by renal status is also illustrated in Figure <xref ref-type="fig" rid="F2">2</xref>. Febuxostat 80 mg was significantly more efficacious than both febuxostat 40 mg and allopurinol in subjects with moderate renal impairment (<italic>p </italic>&#x02264; 0.001) and superior to allopurinol in subjects with mild renal impairment (<italic>p </italic>= 0.004). Within the mild or within the moderate renal impairment categories the percentage of subjects achieving final visit sUA &#x0003c;6.0 mg/dL was numerically greater in the febuxostat 40 mg group than in the allopurinol group, but the differences were not statistically significant.</p><p>The mean percent change (&#x000b1;standard deviation) in sUA from baseline to the final visit for the febuxostat 40 mg, febuxostat 80 mg, and allopurinol 200/300 mg groups was -36.9% (&#x000b1;16.8), -48.1% (&#x000b1;20.0), and -31.1% (&#x000b1;16.0), respectively. The mean percent change in sUA from baseline at months 2, 4, and 6 are illustrated in Figure <xref ref-type="fig" rid="F3">3</xref>. These percent changes were significantly greater in the febuxostat 80 mg group compared with either the febuxostat 40 mg or allopurinol 200/300 mg groups (<italic>p </italic>&#x0003c; 0.001 for both comparisons) and also in the febuxostat 40 mg group compared with the allopurinol 200/300 mg group (<italic>p </italic>= 0.011).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Mean Percent Change From Baseline In Serum Urate at Each Scheduled Visit</bold>. <sup>a</sup><italic>p </italic>&#x0003c; 0.001 vs allopurinol; <sup>b</sup><italic>p </italic>&#x0003c; 0.001 vs febuxostat 40 mg; <sup>c</sup><italic>p </italic>&#x02264; 0.027 vs allopurinol. Error bars represent standard deviation.</p></caption><graphic xlink:href="1471-2318-12-11-3"/></fig><p>The proportion of subjects requiring treatment for gout flares declined in all treatment groups during the course of the study. In the febuxostat 40 mg and 80 mg treatment groups, flare rates during the first 2 months were 16.5% (19/115) and 18.0% (23/128), respectively. During the last 2 months of treatment, rates were 9.5% (9/95) and 6.6% (7/106), respectively. Treatment for gout flares was required by 4.6% (6/131) of subjects in the allopurinol 200/300 mg group during the first 2 months; this rate decreased to 0.9% (1/106) during the last 2 months. Flare rates were significantly higher in the febuxostat 40 mg and 80 mg groups compared with the allopurinol group (<italic>p </italic>&#x02264; 0.05) during the first 2 months of the study, and in the febuxostat 40 mg group compared with the allopurinol group (<italic>p </italic>&#x02264; 0.05) during the last 2 months.</p><p>Overall, rates of AEs were low and similar across treatment groups; the most frequently reported AEs were diarrhea (9.6%), upper respiratory tract infection (7.8%), and musculoskeletal and connective tissue signs and symptoms (6.1%) (Table <xref ref-type="table" rid="T3">3</xref>). Rates of abnormal liver function analyses were reported in 4.3%, 3.9%, and 2.3% of subjects in the febuxostat 40 mg, febuxostat 80 mg, and allopurinol 200/300 mg groups, respectively. The percentage of subjects who discontinued prematurely from the study due to abnormal liver function analyses was 0.9%, 1.6%, and 0 in the febuxostat 40 mg, febuxostat 80 mg, and allopurinol groups, respectively. Elevated liver function tests are listed by treatment group in Table <xref ref-type="table" rid="T3">3</xref>. No subjects experienced concurrent elevated ALT/bilirubin, AST/bilirubin, ALT/alkaline phosphatase, AST/alkaline phosphatase, or ALT/AST/bilirubin levels. Serious AEs occurred in 7.8%, 6.3%, and 11.5% of subjects in the febuxostat 40 mg, febuxostat 80 mg, and allopurinol 200/300 mg groups, respectively. Cardiac disorders and infections were the most frequently reported serious AEs; in the febuxostat 40 mg, febuxostat 80 mg, and allopurinol groups, 0.9%, 1.6%, and 3.1% of subjects reported cardiac disorders and 1.7%, 0.8%, and 3.1% reported infections and infestations. Two subjects in this elderly population died during the study; both were in the allopurinol group. One subject died from hypertensive heart disease, and the other from postsurgical complications related to lung adenocarcinoma and lymphocytic leukemia.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Most frequently reported adverse events<sup>a </sup>and elevated serum liver function tests, by treatment group</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left">Febuxostat 40 mg<break/>N = 115</th><th align="left">Febuxostat 80 mg<break/>N = 128</th><th align="left">Allopurinol 200/300 mg<break/>N = 131</th></tr></thead><tbody><tr><td align="left"><bold>Total subjects reporting </bold>&#x02265;<bold>1 AE</bold>, n (%)</td><td align="left">n (%)70 (60.9)</td><td align="left">75 (58.6)</td><td align="left">81 (61.8)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left"><bold>Most frequently reported<sup>b </sup>AEs</bold>, n (%)</td><td/><td/><td/></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Diarrhea (non infectious)</td><td align="left">14 (12.2)</td><td align="left">12 (9.4)</td><td align="left">10 (7.6)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Musculoskeletal and connective tissue signs and symptoms</td><td align="left">10 (8.7)</td><td align="left">7 (5.5)</td><td align="left">6 (4.6)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Upper respiratory tract infections</td><td align="left">9 (7.8)</td><td align="left">11 (8.6)</td><td align="left">9 (6.9)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Neurological signs and symptoms</td><td align="left">8 (7.0)</td><td align="left">1 (0.8)</td><td align="left">1 (0.8)</td></tr><tr><td align="left">(Dizziness)</td><td align="left">7 (6.1)</td><td align="left">1 (0.8)</td><td align="left">1 (0.8)</td></tr><tr><td align="left">(Presyncope)</td><td align="left">1 (0.9)</td><td align="left">0</td><td align="left">0</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Joint related signs and symptoms</td><td align="left">2 (1.7)</td><td align="left">8 (6.3)</td><td align="left">3 (2.3)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Lower respiratory tract and lung infections</td><td align="left">2 (1.7)</td><td align="left">3 (2.3)</td><td align="left">7 (5.3)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Headaches</td><td align="left">6 (5.2)</td><td align="left">2 (1.6)</td><td align="left">3 (2.3)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Nausea and vomiting</td><td align="left">6 (5.2)</td><td align="left">1 (0.8)</td><td align="left">4 (3.1)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left"><bold>Elevated liver function tests</bold>, n/N (%)</td><td/><td/><td/></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">ALT</td><td/><td/><td/></tr><tr><td align="left">&#x02265;2X ULN</td><td align="left">4/106 (4)</td><td align="left">4/117 (3)</td><td align="left">3/115 (3)</td></tr><tr><td align="left">&#x02265;3X ULN</td><td align="left">2/106 (2)</td><td align="left">0/117</td><td align="left">1/115 (&#x0003c;1)</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">AST</td><td/><td/><td/></tr><tr><td align="left">&#x02265;2X ULN</td><td align="left">3/106 (3)</td><td align="left">1/117 (&#x0003c;1)</td><td align="left">0/115</td></tr><tr><td align="left">&#x02265;3X ULN</td><td align="left">2/106 (2)</td><td align="left">0/117</td><td align="left">0/115</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">ALT and AST concurrently</td><td/><td/><td/></tr><tr><td align="left">&#x02265;3X ULN</td><td align="left">2/106 (2)</td><td align="left">0/117</td><td align="left">0/115</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>AEs are reported by Medical Dictionary for Regulatory Activities high-level term.</p><p><sup>b</sup>Most frequently reported AEs are those which occurred in &#x02265;5% of elderly subjects in any treatment group.</p><p>AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal.</p></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>This is the first analysis of randomized, controlled clinical trial data to specifically examine the efficacy and safety of ULT with febuxostat or allopurinol in a population of elderly gout subjects with significant proportions of renal impairment and other comorbidities. In this cohort, ULT with either dose of febuxostat (40 mg or 80 mg) was significantly more efficacious than fixed doses of allopurinol 200/300 mg in achieving the therapeutic sUA goal (&#x0003c;6.0 mg/dL). In the total CONFIRMS study population, the efficacy of febuxostat 40 mg was comparable to that of allopurinol [<xref ref-type="bibr" rid="B13">13</xref>]. In this analysis, the greater efficacy of febuxostat 40 mg over allopurinol 200/300 mg can be attributed to the very high proportion of elderly patients with mild or moderate renal impairment.</p><p>Flare rates declined markedly in this group, although they were persistently higher in either febuxostat group compared with the allopurinol group. This may reflect more rapid, profound urate lowering in the febuxostat groups. The paradoxical relationship between the extent of sUA reduction and increasing flares upon initial ULT is well recognized [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]; rapid lowering of sUA leads to mobilization of monosodium urate crystals from the body's urate pools, thus triggering an inflammatory response [<xref ref-type="bibr" rid="B19">19</xref>]. It has also been demonstrated that the continued use of ULT for up to 5 years leads to near elimination of gout flares [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>].</p><p>ULT with either febuxostat or allopurinol was well tolerated in this population, with AE rates similar to those reported for the entire CONFIRMS cohort [<xref ref-type="bibr" rid="B13">13</xref>]. Importantly, despite the high percentage of elderly subjects with cardiovascular disease, the rates of cardiovascular events were low and comparable across treatment groups. This reflects the lack of any significant differences in adjudicated cardiovascular AEs as previously reported across treatment groups for the full CONFIRMS population [<xref ref-type="bibr" rid="B13">13</xref>].</p><p>As the prevalence of gout among the elderly continues to rise [<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B24">24</xref>], optimal management of chronic gout and its underlying hyperuricemia is necessary to improve clinical outcomes and reduce healthcare utilization and associated costs. Achievement and long-term maintenance of sUA &#x0003c;6.0 mg/dL leads to reduction of tophi and near-elimination of acute flares [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B25">25</xref>-<xref ref-type="bibr" rid="B27">27</xref>], and may stabilize or improve renal function in gout patients [<xref ref-type="bibr" rid="B28">28</xref>].</p><p>Gout has been identified as an independent risk factor for diabetes, cardiovascular disease, and all-cause and cardiovascular-related mortality [<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B34">34</xref>]. While ULT has not been approved for the management of asymptomatic hyperuricemia, recent studies have suggested the cardiovascular-protective impact of lowering sUA levels [<xref ref-type="bibr" rid="B35">35</xref>], thereby providing potential additional clinical benefit to properly managed gout patients.</p><p>Elderly patients have a high incidence of components of the metabolic syndrome (hypertension, obesity, dyslipidemia, insulin resistance) and declining renal function, which may impair handling of the uric acid load. This, combined with the associated concomitant medication use, which impacts both renal function and uric acid [<xref ref-type="bibr" rid="B36">36</xref>], may further increase hyperuricemia. As a result, elderly gout patients are more challenging to manage. Recently, Keenan et al. [<xref ref-type="bibr" rid="B37">37</xref>] have documented high rates of inappropriate prescribing patterns of gout medications related to contraindicated concomitant medications for other comorbidities. Even cardioprotective use of low-dose aspirin (75-325 mg/day) can impair renal function and uric acid handling in elderly patients [<xref ref-type="bibr" rid="B38">38</xref>]. In elderly patients on thiazide diuretics, which increase the net reabsorption of uric acid in the proximal tubule of the nephron [<xref ref-type="bibr" rid="B39">39</xref>], the adjusted relative risk for the onset of gout, as documented by initiation of anti-gout therapy, was 1.99 (95% CI 1.21-3.26) [<xref ref-type="bibr" rid="B40">40</xref>]. Gout management can be further complicated by low therapeutic compliance; older gout patients have suboptimal adherence to ULT compared with therapies for other chronic illnesses [<xref ref-type="bibr" rid="B41">41</xref>].</p><p>Retrospective analyses of managed care databases reveal that elderly gout patients have higher all-cause healthcare utilization and costs compared with patients without gout, and this rises with increasing sUA [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B42">42</xref>,<xref ref-type="bibr" rid="B43">43</xref>]. Comparison of managed care database claims of 11,935 gout patients &#x02265;65 years of age and matched non-gout patients found that the adjusted difference in total 12-month all-cause healthcare costs was $3,038 (<italic>p </italic>&#x0003c; 0.001; 2005 USD) [<xref ref-type="bibr" rid="B42">42</xref>]. Gout-related costs represent approximately 6% of total healthcare costs for elderly gout patients [<xref ref-type="bibr" rid="B42">42</xref>]. Along with the expected higher rate of gout-related medication use, Hanly et al. [<xref ref-type="bibr" rid="B36">36</xref>] reported that compared with age- and sex-matched controls, elderly gout patients had significantly higher (<italic>p </italic>&#x0003c; 0.0001) utilization rates of diuretics and insulin, which can increase sUA. Higher utilization rates (<italic>p </italic>&#x0003c; 0.0001) were also reported for beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and calcium channel blockers, a reflection of higher comorbidity rates in the gout cohort [<xref ref-type="bibr" rid="B36">36</xref>]. In addition, higher rates (<italic>p </italic>&#x0003c; 0.0001) of use of gastroprotective agents were noted, likely due to the higher NSAID usage for treatment of flares [<xref ref-type="bibr" rid="B36">36</xref>]. Additional database analyses of 2,237 elderly gout patients have shown that among those with higher sUA (&#x0003e;9.0 mg/dL), compared to patients with well-controlled sUA (&#x0003c;6.0 mg/dL), there was a higher frequency of flares, and significantly higher gout-related ($620 vs $264 per flare; <italic>p </italic>&#x0003c; 0.0001) and total healthcare costs ($4,944 vs $2,389 per flare; <italic>p </italic>&#x0003c; 0.0001) [<xref ref-type="bibr" rid="B43">43</xref>].</p><p>This study is not without limitations, the first of which is its post hoc nature. Even so, the data presented here are the first gathered from an RCT and provide evidence for the use of febuxostat as an option for the management of chronic grout in the elderly, particularly those with mild or moderate renal impairment. A second limitation of this analysis is the use of commonly prescribed [<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>] fixed doses of allopurinol determined by renal function. Guideline recommendations [<xref ref-type="bibr" rid="B46">46</xref>] to start with a low dose of allopurinol and slowly titrate up are based on an outdated, single, noncomparative study of 78 patients with renal insufficiency who all developed severe allopurinol hypersensitivity [<xref ref-type="bibr" rid="B5">5</xref>]. Failure to achieve target sUA with guideline-recommended doses of allopurinol has been documented [<xref ref-type="bibr" rid="B6">6</xref>]. In 2 recent small trials [<xref ref-type="bibr" rid="B47">47</xref>,<xref ref-type="bibr" rid="B48">48</xref>], a total of 81 gout patients, including those with mild or moderate renal impairment, received increasing allopurinol doses above creatinine clearance-based dosing guidelines, which led to improved urate-lowering efficacy without increased toxicity. Due to the very limited data regarding the safety of high doses of allopurinol in patients with renal insufficiency, allopurinol dosing in this population remains controversial [<xref ref-type="bibr" rid="B49">49</xref>], and we cannot speculate whether allopurinol dose titration in the CONFIRMS study, and more specifically among this elderly subgroup, would have led to improved efficacy without increased AEs. Additional studies addressing the safety of allopurinol dose titration with much greater numbers of subjects with renal impairment are needed. The doses of allopurinol used in the CONFIRMS trial reflect dosing commonly utilized in clinical practice [<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>]; therefore, the data presented here can be applied to real-world management of elderly gout patients.</p><p>Optimal management can lead to relief from the clinical manifestations of gout and possibly reduce healthcare utilization. Additional analyses are needed to confirm that proper sUA management of elderly gout patients reduces healthcare utilization and associated costs. Our results suggest that despite high rates of comorbidities, including renal impairment, the hyperuricemia of elderly gout patients may be more effectively managed with approved doses of febuxostat, with low risk of side effects.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>This analysis of 374 elderly gout subjects demonstrates that ULT with febuxostat 80 mg or 40 mg once daily leads to significantly more subjects achieving a therapeutic goal of sUA &#x0003c;6.0 mg/dL than commonly used doses of allopurinol (200 or 300 mg). ULT was well tolerated despite high rates of comorbidities and concomitant medication use. These results, along with other supporting data, suggest that the underlying hyperuricemia of gout in elderly patients can be more effectively managed with either dose of febuxostat, especially in those patients with mild to moderate renal impairment.</p></sec><sec><title>Abbreviations</title><p>ULT: urate-lowering therapies; XO: xanthine oxidase; RCT: randomized controlled trial; sUA: serum urate; eCLcr: estimated creatinine clearance; AE: adverse event; ITT: intent-to-treat</p></sec><sec><title>Competing interests</title><p>Pat MacDonald, Barbara Hunt, and Robert L. Jackson are all employees of Takeda Global Research &#x00026; Development Center, Inc, and were employees of TAP Pharmaceutical Products, Inc, at the time of the study conduct. The study sponsor, Takeda Global Research &#x00026; Development Center, Inc, was involved in the study design, protocols, subject recruitment, data collections and analyses.</p></sec><sec><title>Authors' contributions</title><p>All authors were involved in study concept and design, acquisition of data, data analysis and interpretation, and preparation of the manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2318/12/11/prepub">http://www.biomedcentral.com/1471-2318/12/11/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>The CONFIRMS study (NCT# 00430248) was fully funded by TAP Pharmaceutical Products, Inc, which is now a part of Takeda Global Research &#x00026; Development Center, Inc, Deerfield, IL. The authors would like to thank Dr. Eswar Krishnan for his critical reviews of the manuscript during its development. Assistance in manuscript preparation was provided by Meryl Gersh, PhD, of AlphaBioCom, LLC, in King of Prussia, PA, and was funded by Takeda Pharmaceuticals USA, Inc.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Krishnan</surname><given-names>E</given-names></name><name><surname>Lienesch</surname><given-names>D</given-names></name><name><surname>Kwoh</surname><given-names>CK</given-names></name><article-title>Gout in ambulatory care settings in the United States</article-title><source>J Rheumatol</source><year>2008</year><volume>35</volume><fpage>498</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">18260174</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="book"><collab>National Center for Health Statistics</collab><source>Health, United States, 2009: With special feature on medical technology</source><year>2010</year><publisher-name>Hyattsville: Centers for Disease Control. U.S. Department of Health and Human Services</publisher-name></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Bartels</surname><given-names>EC</given-names></name><name><surname>Matossian</surname><given-names>GS</given-names></name><article-title>Gout: six-year follow-up on probenecid (benemid) therapy</article-title><source>Arthritis Rheum</source><year>1959</year><volume>2</volume><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1002/1529-0131(195906)2:3&#x0003c;193::AID-ART1780020302&#x0003e;3.0.CO;2-8</pub-id><pub-id pub-id-type="pmid">13662213</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Kang</surname><given-names>DH</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><article-title>Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease</article-title><source>Semin Nephrol</source><year>2005</year><volume>25</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.semnephrol.2004.10.001</pub-id><pub-id pub-id-type="pmid">15660334</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Hande</surname><given-names>KR</given-names></name><name><surname>Noone</surname><given-names>RM</given-names></name><name><surname>Stone</surname><given-names>WJ</given-names></name><article-title>Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency</article-title><source>Am J Med</source><year>1984</year><volume>76</volume><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">6691361</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Dalbeth</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Stamp</surname><given-names>L</given-names></name><name><surname>Gow</surname><given-names>P</given-names></name><article-title>Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout</article-title><source>J Rheumatol</source><year>2006</year><volume>33</volume><fpage>1646</fpage><lpage>1650</lpage><pub-id pub-id-type="pmid">16783857</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Takano</surname><given-names>Y</given-names></name><name><surname>Hase-Aoki</surname><given-names>K</given-names></name><name><surname>Horiuchi</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Kasahara</surname><given-names>Y</given-names></name><name><surname>Kondo</surname><given-names>S</given-names></name><name><surname>Becker</surname><given-names>MA</given-names></name><article-title>Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase</article-title><source>Life Sci</source><year>2005</year><volume>76</volume><fpage>1835</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2004.10.031</pub-id><pub-id pub-id-type="pmid">15698861</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="book"><source>Uloric<sup>&#x000ae; </sup>Full Prescribing Information</source><year>2011</year><publisher-name>Deerfield, IL: Takeda Pharmaceuticals North America, Inc.</publisher-name></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Becker</surname><given-names>MA</given-names></name><name><surname>Kisicki</surname><given-names>J</given-names></name><name><surname>Khosravan</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Mulford</surname><given-names>D</given-names></name><name><surname>Hunt</surname><given-names>B</given-names></name><name><surname>MacDonald</surname><given-names>P</given-names></name><name><surname>Joseph-Ridge</surname><given-names>N</given-names></name><article-title>Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers</article-title><source>Nucleosides Nucleotides Nucleic Acids</source><year>2004</year><volume>23</volume><fpage>1111</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1081/NCN-200027372</pub-id><pub-id pub-id-type="pmid">15571211</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Khosravan</surname><given-names>R</given-names></name><name><surname>Kukulka</surname><given-names>MJ</given-names></name><name><surname>Wu</surname><given-names>JT</given-names></name><name><surname>Joseph-Ridge</surname><given-names>N</given-names></name><name><surname>Vernillet</surname><given-names>L</given-names></name><article-title>The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase</article-title><source>J Clin Pharmacol</source><year>2008</year><volume>48</volume><fpage>1014</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1177/0091270008322035</pub-id><pub-id pub-id-type="pmid">18635756</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Khosravan</surname><given-names>R</given-names></name><name><surname>Grabowski</surname><given-names>BA</given-names></name><name><surname>Mayer</surname><given-names>MD</given-names></name><name><surname>Wu</surname><given-names>JT</given-names></name><name><surname>Joseph-Ridge</surname><given-names>N</given-names></name><name><surname>Vernillet</surname><given-names>L</given-names></name><article-title>The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase</article-title><source>J Clin Pharmacol</source><year>2006</year><volume>46</volume><fpage>88</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1177/0091270005282634</pub-id><pub-id pub-id-type="pmid">16397288</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Hoshide</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Kubo</surname><given-names>J</given-names></name><name><surname>Tsuchimoto</surname><given-names>M</given-names></name><name><surname>Komoriya</surname><given-names>K</given-names></name><name><surname>Ohno</surname><given-names>I</given-names></name><name><surname>Hosoya</surname><given-names>T</given-names></name><article-title>PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment</article-title><source>Nucleosides Nucleotides Nucleic Acids</source><year>2004</year><volume>23</volume><fpage>1117</fpage><lpage>1118</lpage><pub-id pub-id-type="doi">10.1081/NCN-200027377</pub-id><pub-id pub-id-type="pmid">15571212</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Becker</surname><given-names>MA</given-names></name><name><surname>Schumacher</surname><given-names>HR</given-names></name><name><surname>Espinoza</surname><given-names>LR</given-names></name><name><surname>Wells</surname><given-names>AF</given-names></name><name><surname>Macdonald</surname><given-names>P</given-names></name><name><surname>Lloyd</surname><given-names>E</given-names></name><name><surname>Lademacher</surname><given-names>C</given-names></name><article-title>The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial</article-title><source>Arthritis Res Ther</source><year>2010</year><volume>12</volume><fpage>R63</fpage><pub-id pub-id-type="doi">10.1186/ar2978</pub-id><pub-id pub-id-type="pmid">20370912</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Wallace</surname><given-names>SL</given-names></name><name><surname>Robinson</surname><given-names>H</given-names></name><name><surname>Masi</surname><given-names>AT</given-names></name><name><surname>Decker</surname><given-names>JL</given-names></name><name><surname>McCarty</surname><given-names>DJ</given-names></name><name><surname>Yu</surname><given-names>TF</given-names></name><article-title>Preliminary criteria for the classification of the acute arthritis of primary gout</article-title><source>Arthritis Rheum</source><year>1977</year><volume>20</volume><fpage>895</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1002/art.1780200320</pub-id><pub-id pub-id-type="pmid">856219</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Cockcroft</surname><given-names>DW</given-names></name><name><surname>Gault</surname><given-names>MH</given-names></name><article-title>Prediction of creatinine clearance from serum creatinine</article-title><source>Nephron</source><year>1976</year><volume>16</volume><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1159/000180580</pub-id><pub-id pub-id-type="pmid">1244564</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Robert</surname><given-names>S</given-names></name><name><surname>Zarowitz</surname><given-names>BJ</given-names></name><name><surname>Peterson</surname><given-names>EL</given-names></name><name><surname>Dumler</surname><given-names>F</given-names></name><article-title>Predictability of creatinine clearance estimates in critically ill patients</article-title><source>Crit Care Med</source><year>1993</year><volume>21</volume><fpage>1487</fpage><lpage>1495</lpage><pub-id pub-id-type="doi">10.1097/00003246-199310000-00016</pub-id><pub-id pub-id-type="pmid">8403957</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Becker</surname><given-names>MA</given-names></name><name><surname>MacDonald</surname><given-names>PA</given-names></name><name><surname>Hunt</surname><given-names>BJ</given-names></name><name><surname>Lademacher</surname><given-names>C</given-names></name><name><surname>Joseph-Ridge</surname><given-names>N</given-names></name><article-title>Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy</article-title><source>Nucleosides Nucleotides Nucleic Acids</source><year>2008</year><volume>27</volume><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1080/15257770802136032</pub-id><pub-id pub-id-type="pmid">18600509</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Wortmann</surname><given-names>RL</given-names></name><name><surname>Macdonald</surname><given-names>PA</given-names></name><name><surname>Hunt</surname><given-names>B</given-names></name><name><surname>Jackson</surname><given-names>RL</given-names></name><article-title>Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials</article-title><source>Clin Ther</source><year>2010</year><volume>32</volume><fpage>2386</fpage><lpage>2397</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2011.01.008</pub-id><pub-id pub-id-type="pmid">21353107</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Martinon</surname><given-names>F</given-names></name><article-title>Mechanisms of uric acid crystal-mediated autoinflammation</article-title><source>Immunol Rev</source><year>2010</year><volume>233</volume><fpage>218</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1111/j.0105-2896.2009.00860.x</pub-id><pub-id pub-id-type="pmid">20193002</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Becker</surname><given-names>MA</given-names></name><name><surname>Schumacher</surname><given-names>HR</given-names></name><name><surname>MacDonald</surname><given-names>PA</given-names></name><name><surname>Lloyd</surname><given-names>E</given-names></name><name><surname>Lademacher</surname><given-names>C</given-names></name><article-title>Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout</article-title><source>J Rheumatol</source><year>2009</year><volume>36</volume><fpage>1273</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.3899/jrheum.080814</pub-id><pub-id pub-id-type="pmid">19286847</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Schumacher</surname><given-names>HR</given-names><suffix>Jr</suffix></name><name><surname>Becker</surname><given-names>MA</given-names></name><name><surname>Lloyd</surname><given-names>E</given-names></name><name><surname>MacDonald</surname><given-names>PA</given-names></name><name><surname>Lademacher</surname><given-names>C</given-names></name><article-title>Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study</article-title><source>Rheumatology (Oxford)</source><year>2009</year><volume>48</volume><fpage>188</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">19141576</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Arromdee</surname><given-names>E</given-names></name><name><surname>Michet</surname><given-names>CJ</given-names></name><name><surname>Crowson</surname><given-names>CS</given-names></name><name><surname>O'Fallon</surname><given-names>WM</given-names></name><name><surname>Gabriel</surname><given-names>SE</given-names></name><article-title>Epidemiology of gout: is the incidence rising?</article-title><source>J Rheumatol</source><year>2002</year><volume>29</volume><fpage>2403</fpage><lpage>2406</lpage><pub-id pub-id-type="pmid">12415600</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Wallace</surname><given-names>KL</given-names></name><name><surname>Riedel</surname><given-names>AA</given-names></name><name><surname>Joseph-Ridge</surname><given-names>N</given-names></name><name><surname>Wortmann</surname><given-names>R</given-names></name><article-title>Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population</article-title><source>J Rheumatol</source><year>2004</year><volume>31</volume><fpage>1582</fpage><lpage>1587</lpage><pub-id pub-id-type="pmid">15290739</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Lawrence</surname><given-names>RC</given-names></name><name><surname>Felson</surname><given-names>DT</given-names></name><name><surname>Helmick</surname><given-names>CG</given-names></name><name><surname>Arnold</surname><given-names>LM</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Deyo</surname><given-names>RA</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Hirsch</surname><given-names>R</given-names></name><name><surname>Hochberg</surname><given-names>MC</given-names></name><name><surname>Hunder</surname><given-names>GG</given-names></name><name><surname>Jordan</surname><given-names>JM</given-names></name><name><surname>Katz</surname><given-names>JN</given-names></name><name><surname>Kremers</surname><given-names>HM</given-names></name><name><surname>Wolfe</surname><given-names>F</given-names></name><article-title>Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II</article-title><source>Arthritis Rheum</source><year>2008</year><volume>58</volume><fpage>26</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1002/art.23176</pub-id><pub-id pub-id-type="pmid">18163497</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Shoji</surname><given-names>A</given-names></name><name><surname>Yamanaka</surname><given-names>H</given-names></name><name><surname>Kamatani</surname><given-names>N</given-names></name><article-title>A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy</article-title><source>Arthritis Rheum</source><year>2004</year><volume>51</volume><fpage>321</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1002/art.20405</pub-id><pub-id pub-id-type="pmid">15188314</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Perez-Ruiz</surname><given-names>F</given-names></name><name><surname>Calabozo</surname><given-names>M</given-names></name><name><surname>Pijoan</surname><given-names>JI</given-names></name><name><surname>Herrero-Beites</surname><given-names>AM</given-names></name><name><surname>Ruibal</surname><given-names>A</given-names></name><article-title>Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout</article-title><source>Arthritis Rheum</source><year>2002</year><volume>47</volume><fpage>356</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1002/art.10511</pub-id><pub-id pub-id-type="pmid">12209479</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Perez-Ruiz</surname><given-names>F</given-names></name><name><surname>Liote</surname><given-names>F</given-names></name><article-title>Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?</article-title><source>Arthritis Rheum</source><year>2007</year><volume>57</volume><fpage>1324</fpage><lpage>1328</lpage><pub-id pub-id-type="doi">10.1002/art.23007</pub-id><pub-id pub-id-type="pmid">17907217</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Whelton</surname><given-names>A</given-names></name><name><surname>Macdonald</surname><given-names>PA</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Hunt</surname><given-names>B</given-names></name><name><surname>Gunawardhana</surname><given-names>L</given-names></name><article-title>Renal function in gout: long-term treatment effects of febuxostat</article-title><source>J Clin Rheumatol</source><year>2011</year><volume>17</volume><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">21169856</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>HK</given-names></name><name><surname>De Vera</surname><given-names>MA</given-names></name><name><surname>Krishnan</surname><given-names>E</given-names></name><article-title>Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile</article-title><source>Rheumatology (Oxford)</source><year>2008</year><volume>47</volume><fpage>1567</fpage><lpage>1570</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/ken305</pub-id><pub-id pub-id-type="pmid">18710901</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Dehghan</surname><given-names>A</given-names></name><name><surname>van Hoek</surname><given-names>M</given-names></name><name><surname>Sijbrands</surname><given-names>EJ</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Witteman</surname><given-names>JC</given-names></name><article-title>High serum uric acid as a novel risk factor for type 2 diabetes</article-title><source>Diabetes Care</source><year>2008</year><volume>31</volume><fpage>361</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">17977935</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>HK</given-names></name><name><surname>Curhan</surname><given-names>G</given-names></name><article-title>Independent impact of gout on mortality and risk for coronary heart disease</article-title><source>Circulation</source><year>2007</year><volume>116</volume><fpage>894</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.703389</pub-id><pub-id pub-id-type="pmid">17698728</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>De Vera</surname><given-names>MA</given-names></name><name><surname>Rahman</surname><given-names>MM</given-names></name><name><surname>Bhole</surname><given-names>V</given-names></name><name><surname>Kopec</surname><given-names>JA</given-names></name><name><surname>Choi</surname><given-names>HK</given-names></name><article-title>Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study</article-title><source>Ann Rheum Dis</source><year>2010</year><volume>69</volume><fpage>1162</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1136/ard.2009.122770</pub-id><pub-id pub-id-type="pmid">20124358</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Krishnan</surname><given-names>E</given-names></name><name><surname>Baker</surname><given-names>JF</given-names></name><name><surname>Furst</surname><given-names>DE</given-names></name><name><surname>Schumacher</surname><given-names>HR</given-names></name><article-title>Gout and the risk of acute myocardial infarction</article-title><source>Arthritis Rheum</source><year>2006</year><volume>54</volume><fpage>2688</fpage><lpage>2696</lpage><pub-id pub-id-type="doi">10.1002/art.22014</pub-id><pub-id pub-id-type="pmid">16871533</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Krishnan</surname><given-names>E</given-names></name><name><surname>Svendsen</surname><given-names>K</given-names></name><name><surname>Neaton</surname><given-names>JD</given-names></name><name><surname>Grandits</surname><given-names>G</given-names></name><name><surname>Kuller</surname><given-names>LH</given-names></name><article-title>Long-term cardiovascular mortality among middle-aged men with gout</article-title><source>Arch Intern Med</source><year>2008</year><volume>168</volume><fpage>1104</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1001/archinte.168.10.1104</pub-id><pub-id pub-id-type="pmid">18504339</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Krishnan</surname><given-names>E</given-names></name><article-title>Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout</article-title><source>Rheumatology (Oxford)</source><year>2010</year><volume>49</volume><fpage>1229</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keq037</pub-id><pub-id pub-id-type="pmid">20202928</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Hanly</surname><given-names>JG</given-names></name><name><surname>Skedgel</surname><given-names>C</given-names></name><name><surname>Sketris</surname><given-names>I</given-names></name><name><surname>Cooke</surname><given-names>C</given-names></name><name><surname>Linehan</surname><given-names>T</given-names></name><name><surname>Thompson</surname><given-names>K</given-names></name><name><surname>van Zanten</surname><given-names>SV</given-names></name><article-title>Gout in the elderly-a population health study</article-title><source>J Rheumatol</source><year>2009</year><volume>36</volume><fpage>822</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.3899/jrheum.080768</pub-id><pub-id pub-id-type="pmid">19286852</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Keenan</surname><given-names>RT</given-names></name><name><surname>O'Brien</surname><given-names>WR</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Crittenden</surname><given-names>DB</given-names></name><name><surname>Fisher</surname><given-names>MC</given-names></name><name><surname>Goldfarb</surname><given-names>DS</given-names></name><name><surname>Krasnokutsky</surname><given-names>S</given-names></name><name><surname>Oh</surname><given-names>C</given-names></name><name><surname>Pillinger</surname><given-names>MH</given-names></name><article-title>Prevalence of contraindications and prescription of pharmacologic therapies for gout</article-title><source>Am J Med</source><year>2011</year><volume>124</volume><fpage>155</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2010.09.012</pub-id><pub-id pub-id-type="pmid">21295195</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Caspi</surname><given-names>D</given-names></name><name><surname>Lubart</surname><given-names>E</given-names></name><name><surname>Graff</surname><given-names>E</given-names></name><name><surname>Habot</surname><given-names>B</given-names></name><name><surname>Yaron</surname><given-names>M</given-names></name><name><surname>Segal</surname><given-names>R</given-names></name><article-title>The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients</article-title><source>Arthritis Rheum</source><year>2000</year><volume>43</volume><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1002/1529-0131(200001)43:1&#x0003c;103::AID-ANR13&#x0003e;3.0.CO;2-C</pub-id><pub-id pub-id-type="pmid">10643705</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Reyes</surname><given-names>AJ</given-names></name><article-title>Cardiovascular drugs and serum uric acid</article-title><source>Cardiovasc Drugs Ther</source><year>2003</year><volume>17</volume><fpage>397</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">15107595</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Gurwitz</surname><given-names>JH</given-names></name><name><surname>Kalish</surname><given-names>SC</given-names></name><name><surname>Bohn</surname><given-names>RL</given-names></name><name><surname>Glynn</surname><given-names>RJ</given-names></name><name><surname>Monane</surname><given-names>M</given-names></name><name><surname>Mogun</surname><given-names>H</given-names></name><name><surname>Avorn</surname><given-names>J</given-names></name><article-title>Thiazide diuretics and the initiation of anti-gout therapy</article-title><source>J Clin Epidemiol</source><year>1997</year><volume>50</volume><fpage>953</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1016/S0895-4356(97)00101-7</pub-id><pub-id pub-id-type="pmid">9291881</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Briesacher</surname><given-names>BA</given-names></name><name><surname>Andrade</surname><given-names>SE</given-names></name><name><surname>Fouayzi</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>KA</given-names></name><article-title>Comparison of drug adherence rates among patients with seven different medical conditions</article-title><source>Pharmacotherapy</source><year>2008</year><volume>28</volume><fpage>437</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1592/phco.28.4.437</pub-id><pub-id pub-id-type="pmid">18363527</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>EQ</given-names></name><name><surname>Patel</surname><given-names>PA</given-names></name><name><surname>Yu</surname><given-names>AP</given-names></name><name><surname>Mody</surname><given-names>RR</given-names></name><name><surname>Cahill</surname><given-names>KE</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Krishnan</surname><given-names>E</given-names></name><article-title>Disease-related and all-cause health care costs of elderly patients with gout</article-title><source>J Manag Care Pharm</source><year>2008</year><volume>14</volume><fpage>164</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">18331118</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>EQ</given-names></name><name><surname>Patel</surname><given-names>PA</given-names></name><name><surname>Mody</surname><given-names>RR</given-names></name><name><surname>Yu</surname><given-names>AP</given-names></name><name><surname>Cahill</surname><given-names>KE</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Krishnan</surname><given-names>E</given-names></name><article-title>Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?</article-title><source>J Rheumatol</source><year>2009</year><volume>36</volume><fpage>1032</fpage><lpage>1040</lpage><pub-id pub-id-type="doi">10.3899/jrheum.080487</pub-id><pub-id pub-id-type="pmid">19369467</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Sarawate</surname><given-names>CA</given-names></name><name><surname>Brewer</surname><given-names>KK</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Patel</surname><given-names>PA</given-names></name><name><surname>Schumacher</surname><given-names>HR</given-names></name><name><surname>Saag</surname><given-names>KG</given-names></name><name><surname>Bakst</surname><given-names>AW</given-names></name><article-title>Gout medication treatment patterns and adherence to standards of care from a managed care perspective</article-title><source>Mayo Clin Proc</source><year>2006</year><volume>81</volume><fpage>925</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.4065/81.7.925</pub-id><pub-id pub-id-type="pmid">16835972</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Solomon</surname><given-names>DH</given-names></name><name><surname>Avorn</surname><given-names>J</given-names></name><name><surname>Levin</surname><given-names>R</given-names></name><name><surname>Brookhart</surname><given-names>MA</given-names></name><article-title>Uric acid lowering therapy: prescribing patterns in a large cohort of older adults</article-title><source>Ann Rheum Dis</source><year>2008</year><volume>67</volume><fpage>609</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">17728328</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><name><surname>Bardin</surname><given-names>T</given-names></name><name><surname>Pascual</surname><given-names>E</given-names></name><name><surname>Barskova</surname><given-names>V</given-names></name><name><surname>Conaghan</surname><given-names>P</given-names></name><name><surname>Gerster</surname><given-names>J</given-names></name><name><surname>Jacobs</surname><given-names>J</given-names></name><name><surname>Leeb</surname><given-names>B</given-names></name><name><surname>Liote</surname><given-names>F</given-names></name><name><surname>McCarthy</surname><given-names>G</given-names></name><name><surname>Netter</surname><given-names>P</given-names></name><name><surname>Nuki</surname><given-names>G</given-names></name><name><surname>Perez-Ruiz</surname><given-names>F</given-names></name><name><surname>Pignone</surname><given-names>A</given-names></name><name><surname>Pimentao</surname><given-names>J</given-names></name><name><surname>Punzi</surname><given-names>L</given-names></name><name><surname>Roddy</surname><given-names>E</given-names></name><name><surname>Uhlig</surname><given-names>T</given-names></name><name><surname>Zimmermann-Gorska</surname><given-names>I</given-names></name><article-title>EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)</article-title><source>Ann Rheum Dis</source><year>2006</year><volume>65</volume><fpage>1312</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1136/ard.2006.055269</pub-id><pub-id pub-id-type="pmid">16707532</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Reinders</surname><given-names>MK</given-names></name><name><surname>Haagsma</surname><given-names>C</given-names></name><name><surname>Jansen</surname><given-names>TL</given-names></name><name><surname>van Roon</surname><given-names>EN</given-names></name><name><surname>Delsing</surname><given-names>J</given-names></name><name><surname>van de Laar</surname><given-names>MA</given-names></name><name><surname>Brouwers</surname><given-names>JR</given-names></name><article-title>A randomised controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout</article-title><source>Ann Rheum Dis</source><year>2009</year><volume>68</volume><fpage>892</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1136/ard.2008.091462</pub-id><pub-id pub-id-type="pmid">18633127</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Stamp</surname><given-names>LK</given-names></name><name><surname>O'Donnell</surname><given-names>JL</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>James</surname><given-names>J</given-names></name><name><surname>Frampton</surname><given-names>C</given-names></name><name><surname>Barclay</surname><given-names>ML</given-names></name><name><surname>Chapman</surname><given-names>PT</given-names></name><article-title>Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment</article-title><source>Arthritis Rheum</source><year>2011</year><volume>63</volume><fpage>412</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1002/art.30119</pub-id><pub-id pub-id-type="pmid">21279998</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>El-Zawawy</surname><given-names>H</given-names></name><name><surname>Mandell</surname><given-names>BF</given-names></name><article-title>Managing gout: how is it different in patients with chronic kidney disease?</article-title><source>Cleve Clin J Med</source><year>2010</year><volume>77</volume><fpage>919</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.3949/ccjm.77a.09080</pub-id><pub-id pub-id-type="pmid">21147946</pub-id></mixed-citation></ref></ref-list></back></article>